SequelSEC

PRECISION BIOSCIENCES INC DTIL

Biological Products, (No Diagnostic Substances) · CIK 0001357874 · Fiscal year ends 0521

Revenue
$34.26M
Fiscal year ended 2025-12-31
Operating income
-$52.15M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

PRECISION BIOSCIENCES INC (DTIL) reported revenue of $34.26M and net income of -$45.72M for the fiscal year ended 2025-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from PRECISION BIOSCIENCES INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

PRECISION BIOSCIENCES INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue$34.26M$68.70M$48.73M$25.10M$115.53M$24.28M$22.24M$10.88M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$52.15M-$26.16M-$43.74M-$62.31M-$39.38M-$109.83M-$87.20M-$47.91M
Net income-$45.72M$7.17M-$61.32M-$111.64M-$30.60M-$109.01M-$92.88M-$46.04M
Research & development$54.17M$59.56M$53.38M$46.12M$115.24M$98.06M$82.42M$45.12M
Weighted-average diluted sharesshares 12.83Mshares 6.88Mshares 3.84Mshares 2.93Mshares 58.69MUnavailableUnavailableUnavailable
Pretax income-$45.72M$7.17MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0UnavailableUnavailableUnavailable$23.00KUnavailableUnavailable
Diluted EPS$-3.56$1.04$-15.96$-38.10$-0.52UnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$32.24M$35.30M$39.09M$41.28M$39.67M$36.05M$27.03M$13.67M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

PRECISION BIOSCIENCES INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Cash & equivalents$110.82M$85.90M$116.68M$189.58M$143.66M$89.80M$180.89M$103.19M
Total assets$154.42M$136.39M$159.78M$238.17M$211.50M$150.16M$235.23M$138.60M
Current assets$118.74M$94.99M$136.36M$199.10M$161.75M$105.56M$193.67M$115.68M
Total liabilities$62.17M$80.00M$140.92M$177.74M$120.33M$105.73M$96.92M$98.64M
Current liabilities$8.91M$14.98M$49.99M$59.66M$35.98M$42.83M$26.93M$14.08M
Total equity incl. NCI$92.25M$56.39M$18.86M$60.43M$91.17M$44.42M$138.31M$39.96M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$0$229.00K$901.00K$720.00K$488.00K$10.00M$965.00K$523.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable$22.22M$2.48MUnavailableUnavailableUnavailable
Accounts payable$296.00K$1.31M$2.97M$653.00K$1.14M$792.00K$2.04M$2.22M

Cash flow

PRECISION BIOSCIENCES INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Operating cash flow-$65.84M-$58.44M-$84.11M-$45.75M-$10.85M-$87.39M-$71.02M-$51.72M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$634.00K-$215.00K$5.83M-$3.32M-$5.80M-$5.03M-$24.67M-$15.66M
Financing cash flow$95.16M$50.45M$5.39M$94.98M$70.52M$1.33M$173.37M$107.78M
Net change in cash$28.68M-$8.21M-$72.90M$45.91M$53.86M-$91.09M$77.69M$40.39M
Stock-based compensation$10.19M$12.60M$14.04M$19.20M$16.51M$13.79M$8.94M$2.45M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$1.47M$3.40M$6.82M$7.80M$8.98M$8.78M$5.32M$2.35M

Derived

PRECISION BIOSCIENCES INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-152.2%-38.1%-89.8%-248.3%-34.1%-452.2%-392.1%-440.2%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue29.7%18.3%28.8%76.5%14.3%56.8%40.2%22.5%
Current ratio13.32x6.34x2.73x3.34x4.50x2.46x7.19x8.22x
Revenue YoY growth-50.1%41.0%94.1%-78.3%375.7%9.2%104.3%Unavailable
Net margin-133.4%10.4%-125.8%-444.8%-26.5%-448.9%-417.6%-423.0%
R&D / revenue158.1%86.7%109.5%183.8%99.7%403.8%370.6%414.6%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailable0.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DTIL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.